Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1:9:923308.
doi: 10.3389/fmed.2022.923308. eCollection 2022.

Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials

Nachuan Luo  1   2 , Xun Jiang  1   2 , Meiqi Hao  1   2 , Zige Fang  1   2 , Yiping Wei  3 , Wenxiong Zhang  3
Affiliations

Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials

Nachuan Luo et al. Front Med (Lausanne). .

Abstract

Objective: As monotherapy is insufficient for some patients, the existing fixed-dose combination (FDC) requires two or more daily administrations with declining adherence. The present study compared the efficacy and safety of netarsudil/latanoprost FDC with monotherapy of its individual components in patients with glaucoma.

Methods: A systematic literature search was performed for studies comparing netarsudil/latanoprost fixed-dose combination (FDC) vs. monotherapy in patients with glaucoma. The primary endpoints included intraocular pressure (IOP), intraocular pressure reduction percentage (IOPR%) and adverse events (AEs).

Results: Three randomized controlled trial studies (RCTs) involving 1,692 patients (FDC: 556, netarsudil: 577, latanoprost: 559) were included in this meta-analysis. FDC was more effective than netarsudil, with significantly lower diurnal IOP over three time points (8:00 a.m., 10:00 a.m., 4:00 p.m.), mean diurnal IOP (MD = -2.36 [-3.08, -1.63], P < 0.00001) and higher IOPR% (MD = 9.60 [7.86, 11.33], P < 0.00001). When comparing FDC with latanoprost, both mean diurnal IOP (MD = -1.64 [-2.05, -1.23], P < 0.00001) and diurnal IOP across 3 time points were significantly lower with FDC than with latanoprost, while FDC induced significantly higher IOPR% (MD = 6.09 [4.40, 7.77], P < 0.00001). Incidence of total AEs was similar between netarsudil and FDC, but higher with FDC than with latanoprost.

Conclusion: Netarsudil/latanoprost FDC appears to be superior to netarsudil or latanoprost alone, with better ocular hypotensive effects. However, there are concerns that netarsudil/latanoprost FDC was associated with a significantly higher incidence of AEs specifically compared with latanoprost.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=311956.

Keywords: fixed-dose combination; glaucoma; latanoprost; meta-analysis; netarsudil; topical medication.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of study selection.
Figure 2
Figure 2
Forest plot of WMD of IOP at 3 time points (8:00 a.m., 10:00 a.m., 4:00 p.m.) associated with FDC vs. netarsudil.
Figure 3
Figure 3
Forest plot of WMD of mean diurnal IOP associated with FDC vs. monotherapy.
Figure 4
Figure 4
Forest plot of WMD of IOPR% associated with FDC vs. monotherapy.
Figure 5
Figure 5
Forest plot of WMD of IOP at 3 time points (8:00 a.m., 10:00 a.m., 4:00 p.m.) associated with FDC vs. latanoprost.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Craig JE, Han X, Qassim A, Hassall M, Cooke Bailey JN, Kinzy TG, et al. . Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nat Genet. (2020) 52:160–6. 10.1038/s41588-019-0556-y - DOI - PMC - PubMed
    1. Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, et al. . Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. (2019) 393:1505–16. 10.1016/S0140-6736(18)32213-X - DOI - PMC - PubMed
    1. Mincione F, Nocentini A, Supuran CT. Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov. (2021) 16:1209–25. 10.1080/17460441.2021.1922384 - DOI - PubMed
    1. Park JH, Yoo C, Chung HW, Kim YY. Effect of prostaglandin analogues on anterior scleral thickness and corneal thickness in patients with primary open-angle glaucoma. Sci Rep. (2021) 11:11098. 10.1038/s41598-021-90696-4 - DOI - PMC - PubMed
    1. Ibrahim MM, Maria DN, Mishra SR, Guragain D, Wang X, Jablonski MM. Once daily pregabalin eye drops for management of glaucoma. ACS Nano. (2019) 13:13728–44. 10.1021/acsnano.9b07214 - DOI - PMC - PubMed

Publication types